KIR3DL1 and lymphoma: No positive influence of haplotype B was seen in recent investigations for leukemia (49) but in HLA-matched URD-HSCT of non-Hogdkin lymphoma patients, where KIR B/x grafts led to significant lower relapse after 5 years compared to KIR A/A donors (P = 0.5) (101).